Effect of chronic treatment with octreotide nasal powder on serum levels of growth hormone, insulin-like growth factor 1, insulin-like growth factor binding proteins 1 and 3 in acromegalic patients

Journal of Endocrinological Investigation

Volumn 19, Issue 8, 1996, Pages 548-555

  Invitti, C ^a   Fatti, L ^a   Camboni, M G ^b   Porcu, L ^b   Danesi, L ^a   Delitala, G ^b   Cavagnini, F ^a,c  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY OF SASSARI   (Italy)

^c ISTITUTO AUXOLOGICO ITALIANO   (Italy)

Author keywords

Acromegaly; GH; IGF 1; IGFBP 1; IGFBP 3; Octreotide nasal powder; Somatostatin

Indexed keywords

GROWTH HORMONE; OCTREOTIDE; SOMATOMEDIN BINDING PROTEIN 1; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C;

ACROMEGALY; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG TOLERABILITY; FEMALE; GROWTH HORMONE BLOOD LEVEL; HUMAN; INTRANASAL DRUG ADMINISTRATION; MALE; SIDE EFFECT;

EID: 0029844165     PISSN: 03914097     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03349015     Document Type: Article

References (31)

1. Ezzat S., Redelmeier D.A., Gnehm M., Harris A.G. A prospective multicenter octreotide dose response study in the treatment of acromegaly. J. Endocrinol. Invest. 18: 364, 1995.
2. Lee Vance M., Harris A.G. Long-term treatment of 189 acromegalic patients with the somatostatin analog octreotide. Arch. Intern. Med. 151: 1573, 1991.
3. Lamberts S.W.J., Hofland L.J., de Herder W.W., Kwekkeboom D.J., Reubi J.C., Krenning E.P. Octreotide and related somatostatin analogs in the diagnosis and treatment of pituitary disease and somatostatin receptor scintigraphy. Frontiers Neuroendocrinol. 14: 27, 1993.
4. Chang-DeMoranville B.M., Jackson I. Diagnosis and endocrine testing in acromegaly. Endocrinol. Metab. Clin. North Am. 21: 649, 1992.
5. Baxter R.C. Insulin-like growth factor binding proteins in the human circulation: a review. Horm. Res. 42: 140, 1994.
6. Jorgensen J.O.L., Moller N., Moller J., Weeke J., Blum W.F. Insulin-like growth factors (IGF)-I and -II and IGF binding protein -2, and -3 in patients with acromegaly before and after adenomectomy. Metabolism 43: 579, 1994.
7. Fredstorp L., Werner S., Bang P., Hall K. Inverse correlation between insulin-like growth factor binding protein-1 and insulin in patients with acromegaly during treatment with the somatostatin analogue octreotide. Clin. Endocrinol. (Oxf.) 41: 495, 1994.
8. Grinspoon S., Clemmons D., Swearingen B., Klibanski A. Serum insulin-like growth factor-binding protein-3 levels in the diagnosis of acromegaly. J. Clin. Endocrinol. Metab. 80: 927, 1995.
9. Harris A.G., Weeke J., Christensen S.E., Kaal A., Illum P., Orskov H. Preliminary results with sandostatin nasal powder in acromegalic patients. Metabolism 41: 72, 1992.
10. Daughaday W.H., Starkey R.H., Saltman S., Gavin J.R., Mills-Dunlap B., Heath-Monnig E. Characterization of serum growth hormone (GH) and insulin-like growth factor I in active acromegaly with minimal elevation of serum GH. J. Clin. Endocrinol. Metab. 65: 617, 1987.
11. Giannella-Neto D., Wajchenberg B.L., Mendonca B.B., Almeida S.F., Macchione M., Spencer E.M. Criteria for the cure of acromegaly: comparison between basal growth hormone and somatomedin C plasma concentrations in active and nonactive acromegalic patients. J. Endocrinol. Invest. 11: 57, 1988.
12. der Herder W.W., Uitterlinden P., van der Lely A.J., Lamberts S.W.J. Octreotide, but not bromocriptine, increases circulating insulin-like growth factor binding protein 1 levels in acromegaly. Eur. J. Endocrinol. 133: 195, 1995.
13. Rieu M., Girard F., Bricaire H., Binoux M. The importance of insulin-like growth factor (somatomedin) measurements in the diagnosis and surveillance of acromegaly. J. Clin. Endocrinol. Metab. 55: 147, 1982.
14. Holly J.M.P., Cotterill A.M., Jemmott R.C., Shears D., Al-Othman S., Chard T., Wass J.A.H. Inter-relations between growth hormone, insulin, insulin-like growth factor-I (IGF-I), IGF-binding protein-1 (IGF-BP-1) and sex hormone-binding globulin in acromegaly. Clin. Endocrinol. (Oxf.) 34: 275, 1991.
15. Moses A.C., Molitch M.E., Sawin C.T., Jackson I.M.D., Biller B.J., Furlanetto R., Reichlin S. Bromocriptine therapy in acromegaly: use in patients resistant to conventional therapy and effect on serum levels of somatomedin C. J. Clin Endocrinol. Metab. 53: 752, 1981.
16. Oppizzi G., Petroncini M.M., Dallabonzana D., Cozzi R., Verde G., Chiodini P.G., Liuzzi A. Relationship between somatomedin-C and growth hormone levels in acromegaly: basal and dynamic evaluation. J. Clin. Endocrinol. Metab. 63: 1348, 1986.
17. Lamberts S.W.J., Uitterlinden P., Schuijff P.C., Klijn J.G.M. Therapy of acromegaly with sandostatin: the predictive value of an acute test, the value of somatomedin measurements in dose adjustment and the definition of a biochemical "cure". Clin. Endocrinol. (Oxf.) 29: 411, 1988.
18. Dobrashian R.D., O'Halloran D.J., Hunt A., Beardwell C.G., Shalet S.M. Relationships between insulin-like growth factor- 1 levels and growth hormone concentrations during diurnal profiles and following oral glucose in acromegaly. Clin. Endocrinol. (Oxf.) 38: 589, 1993.
19. Barreca A., Cariola G. Effect of octreotide on circulating IGF-I Chromatographic profile: evidence for an inhibitory action on the formation of the 1 50-kDa ternary complex. Clin. Endocrinol. (Oxf.) 42: 161, 1995.
20. Sugisaki T., Yamada T., Takamatsu K., Noguchi T. The influence of endocrine factors on the serum concentrations of insulin-like growth factor-l (IGF-I) and IGF-binding proteins. J. Endocrinol. 138: 467, 1993.
21. Philip M., Chalew S.A., Kowarski A.A., Stene M.A. Plasma IGFBP-3 and its relationship with quantitative growth hormone secretion in short children. Clin. Endocrinol. (Oxf.) 39: 427, 1993.
22. Quin J.D., Checkley A., Gallagher A., Jones J., MacCuish A.C., Miell J.P. Response of insulin-like growth factor (IGF) -binding protein-1 (IGFBP-1 ) and IGFBP-3 to IGF-I treatment in severe insulin resistance. J. Endocrinol. 141: 177, 1994.
23. Rasmussen M.H., Frystyk J., Andersen T., Breum L., Christiansen J.S., Hilsted J. The impact of obesity, fat distribution, and energy restriction on insulin-like growth factor-1 (IGF-1 ), IGF-binding protein-3, insulin, and growth hormone. Metabolism 43: 315, 1994.
24. Villafuerte B.C., Koop B.L., Pao C., Gu L., Birdsong G.G., Phillips L.S. Coculture of primary rat hepatocytes and non-parenchymal cells permits expression of insulin-like growth factor binding protein-3 in vitro. Endocrinology 134: 2044, 1994.
25. Laursen T., Jorgensen J.O.L., Orskov H., Moller J., Harris A.G., Cristiansen J.S. Effects of octreotide on insulin-like growth factor I and metabolic indices in growth hormone-treated growth hormone-deficient patients. Acta Endocrinol. (Copenh.) 129: 399, 1993.
26. Conover C.A., Lee P.D.K. Insulin regulation of insulin-like growth factor-binding protein production in culture HepG2 cells. J. Clin. Endocrinol. Metab. 70: 1062, 1990.
27. Cotterill A.M., Holly J.M., Amiel S., Wass J.A. Suppression of endogenous insulin secretion regulates the rapid rise of insulin-like growth factor binding protein (IGFBP)-1 levels following acute hypoglycaemia. Clin. Endocrinol. (Oxf.) 38: 633, 1993.
28. Ezzat S., Ren S.G., Braunstein G.D., Melmed S. Octreotide stimulates insulin-like growth factor binding protein-1 (IGFBP1) levels in acromegaly. J. Clin. Endocrinol. Metab. 73: 441, 1991.
29. Ezzat S., Re S.G., Braunstein G.D., Melmed S. Octreotide stimulates insulin-like growth factor-binding protein- 1: a potential pituitary-independent mechanism for drug action. J. Clin. Endocrinol. Metab. 75: 1459, 1992.
30. Orskov H., Wolthers T., Grofte T., Flyvbjerg A., Vilstrup H. Somatostatin-stimulated insulin-like growth factor binding protein-1 release is abolished by hyperinsulinemia. J. Clin. Endocrinol. Metab. 78: 138, 1994.
31. Ren S.G., Ezzat S., Melmed S., Braunstein G.D. Somatostatin analog induces insulin-like growth binding protein-1 (IGFBP-1) expression in human hepatoma cells. Endocrinology 131: 2479, 1992.